---
title: "Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295788544.md"
description: "Pyxis Oncology highlighted MICVO, a first-in-concept extracellular-targeting ADC for EDB+ fibronectin in head-and-neck cancer. Phase 1 data showed responses from 3.6 mg/kg, with confirmed ORR of 50% and 100% disease control at 3.6-5.4 mg/kg in R/M HNSCC. The company selected 5.4 mg/kg for dose expansion, expecting multiple clinical data catalysts in the second half of 2026."
datetime: "2026-08-13T11:17:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295788544.md)
  - [en](https://longbridge.com/en/news/295788544.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295788544.md)
generator: "portal-rs"
---

# Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancer

-   Pyxis Oncology highlighted MICVO, a first-in-concept extracellular-targeting antibody-drug conjugate aimed at EDB+ fibronectin in tumor matrix. \* Phase 1 dose escalation dosed 80 patients across 18 sites, testing 0.3-8 mg/kg every three weeks. \* Responses emerged from 3.6 mg/kg; 3.6-5.4 mg/kg became the focus range for continued development. \* In R/M HNSCC dose escalation, confirmed ORR was 50% with 100% disease control at 3.6 and 5.4 mg/kg. \* 5.4 mg/kg was selected for dose expansion; multiple clinical data catalysts are expected in 2H 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md)

## Related News & Research

- [Bank of America Securities Keeps Their Buy Rating on Agree Realty (ADC)](https://longbridge.com/en/news/296102817.md)
- [Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy | AKTX Stock News](https://longbridge.com/en/news/296232130.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy](https://longbridge.com/en/news/296250397.md)
- [Spago Nanomedical Tumorad-01 DMC says maximum tolerated dose met, adds two patients at 15 MBq/kg for RP2D definition](https://longbridge.com/en/news/296442151.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**